Blog

ICH M15 guideline: What the finalized guideline means for model-informed drug development

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

Certara2026 年 3 月 18 日

Blog

通过模型引导的药物开发促进药物公平：ASCPT 2026 见解

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

Certara2026 年 3 月 11 日

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026 年 3 月 4 日

Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026 年 3 月 3 日

Conference

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Danielle Pillsbury2026 年 3 月 2 日

Blog

拥抱模型引导的药物发现：通往更佳临床疗效之路

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

Certara2026 年 2 月 27 日

博客

Rare disease day 2026: Accelerating rare disease drug development through cross-functional innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

Certara2026 年 2 月 26 日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026 年 2 月 23 日

On-Demand Webinar

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…

Certara2026 年 2 月 23 日

Blog

FAQs: The ICH M15 guideline and what it means for model-informed drug development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

Certara2026 年 2 月 18 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

建模与模拟

ICH M15 guideline: What the finalized guideline means for model-informed drug development

通过模型引导的药物开发促进药物公平：ASCPT 2026 见解

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

Apotekarsocieteten 临床药理学策略在药物开发中的应用

拥抱模型引导的药物发现：通往更佳临床疗效之路

Rare disease day 2026: Accelerating rare disease drug development through cross-functional innovation

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

FAQs: The ICH M15 guideline and what it means for model-informed drug development

订阅时事通讯

快捷链接

解决方案

联系我们